Skip to main content

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Suicidal thoughts and behaviors in adolescents and young adults [see BOXED WARNING and WARNINGS AND PRECAUTIONS]
  • Neuropsychiatric symptoms and suicide risk in smoking cessation treatment [see BOXED WARNING and WARNINGS AND PRECAUTIONS]
  • Hypertension [see WARNINGS AND PRECAUTIONS]
  • Activation of mania or hypomania [see WARNINGS AND PRECAUTIONS]
  • Psychosis and other neuropsychiatric reactions [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions Leading to Discontinuation of Treatment

Adverse reactions were sufficiently troublesome to cause discontinuation of treatment with WELLBUTRIN in approximately 10% of the 2,400 subjects and healthy volunteers who participated in clinical trials during the product's initial development. The more common events causing discontinuation include neuropsychiatric disturbances (3.0%), primarily agitation and abnormalities in mental status; gastrointestinal disturbances (2.1%), primarily nausea and vomiting; neurological disturbances (1.7%), primarily seizures, headaches, and sleep disturbances; and dermatologic problems (1.4%), primarily rashes. It is important to note, however, that many of these events occurred at doses that exceed the recommended daily dose.

Commonly Observed Adverse Reactions

Adverse reactions commonly encountered in subjects treated with WELLBUTRIN are agitation, dry mouth, insomnia, headache/migraine, nausea/vomiting, constipation, tremor, dizziness, excessive sweating, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmia, and auditory disturbance.

Table 2 summarizes the adverse reactions that occurred in placebo-controlled trials at an incidence of at least 1% of subjects receiving WELLBUTRIN and more frequently in these subjects than in the placebo group.

Table 2: Adverse Reactions Reported by at Least 1% of Subjects and at a Greater Frequency Than Placebo in Controlled Clinical Trials

Adverse Reaction WELLBUTRIN
(n = 323) %
(n = 185) %
  Cardiac arrhythmias 5.3 4.3
  Dizziness 22.3 16.2
  Hypertension 4.3 1.6
  Hypotension 2.5 2.2
  Palpitations 3.7 2.2
  Syncope 1.2 0.5
  Tachycardia 10.8 8.6
  Pruritus 2.2 0.0
  Rash 8.0 6.5
  Appetite increase 3.7 2.2
  Constipation 26 17.3
  Dyspepsia 3.1 2.2
  Nausea/vomiting 22.9 18.9
  Impotence 3.4 3.1
  Menstrual complaints 4.7 1.1
  Urinary frequency 2.5 2.2
  Musculoskeletal Arthritis 3.1 2.7
  Akathisia 1.5 1.1
  Cutaneous temperature disturbance 1.9 1.6
  Dry mouth 27.6 18.4
  Excessive sweating 22.3 14.6
  Headache/migraine 25.7 22.2
  Impaired sleep quality 4 1.6
  Insomnia 18.6 15.7
  Sedation 19.8 19.5
  Sensory disturbance 4 3.2
  Tremor 21.1 7.6
  Agitation 31.9 22.2
  Anxiety 3.1 1.1
  Confusion 8.4 4.9
  Decreased libido 3.1 1.6
  Delusions 1.2 1.1
  Euphoria 1.2 0.5
  Hostility 5.6 3.8
  Nonspecific Fever/chills 1.2 0.5
Special Senses
  Auditory disturbance 5.3 3.2
  Blurred vision 14.6 10.3
  Gustatory disturbance 3.1 1.1

Other Adverse Reactions Observed During the Clinical Development of WELLBUTRIN

The conditions and duration of exposure to WELLBUTRIN varied greatly, and a substantial proportion of the experience was gained in open and uncontrolled clinical settings. During this experience, numerous adverse events were reported; however, without appropriate controls, it is impossible to determine with certainty which events were or were not caused by WELLBUTRIN. The following enumeration is organized by organ system and describes events in terms of their relative frequency of reporting in the database.

The following definitions of frequency are used: Frequent adverse reactions are defined as those occurring in at least 1/100 subjects. Infrequent adverse reactions are those occurring in 1/100 to 1/1,000 subjects, while rare events are those occurring in less than 1/1,000 subjects.

Cardiovascular: Frequent was edema; infrequent were chest pain, electrocardiogram (ECG) abnormalities (premature beats and nonspecific ST-T changes), and shortness of breath/dyspnea; rare were flushing, and myocardial infarction.

Dermatologic: Infrequent was alopecia.

Endocrine: Infrequent was gynecomastia; rare was glycosuria.

Gastrointestinal: Infrequent were dysphagia, thirst disturbance, and liver damage/jaundice; rare was intestinal perforation.

Genitourinary: Frequent was nocturia; infrequent were vaginal irritation, testicular swelling, urinary tract infection, painful erection, and retarded ejaculation; rare were enuresis, and urinary incontinence.

Neurological: Frequent were ataxia/incoordination, seizure, myoclonus, dyskinesia, and dystonia; infrequent were mydriasis, vertigo, and dysarthria; rare were electroencephalogram (EEG) abnormality, and impaired attention.

Neuropsychiatric: Frequent were mania/hypomania, increased libido, hallucinations, decrease in sexual function, and depression; infrequent were memory impairment, depersonalization, psychosis, dysphoria, mood instability, paranoia, formal thought disorder, and frigidity; rare was suicidal ideation.

Oral Complaints: Frequent was stomatitis; infrequent were toothache, bruxism, gum irritation, and oral edema.

Respiratory: Infrequent were bronchitis and shortness of breath/dyspnea; rare was pulmonary embolism.

Special Senses: Infrequent was visual disturbance; rare was diplopia.

Nonspecific: Frequent were flu-like symptoms; infrequent was nonspecific pain; rare was overdose.

Altered Appetite and Weight

A weight loss of greater than 5 lbs occurred in 28% of subjects receiving WELLBUTRIN. This incidence is approximately double that seen in comparable subjects treated with tricyclics or placebo. Furthermore, while 35% of subjects receiving tricyclic antidepressants gained weight, only 9.4% of subjects treated with WELLBUTRIN did. Consequently, if weight loss is a major presenting sign of a patient's depressive illness, the anorectic and/or weight reducing potential of WELLBUTRIN should be considered.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of WELLBUTRIN and are not described elsewhere in the label. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body (General): Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble serum sickness.

Cardiovascular: Hypertension (in some cases severe), orthostatic hypotension, third degree heart block.

Endocrine: Syndrome of inappropriate antidiuretic hormone secretion, hyperglycemia, hypoglycemia.

Gastrointestinal: Esophagitis, hepatitis.

Hemic and Lymphatic: Ecchymosis, leukocytosis, leukopenia, thrombocytopenia. Altered PT and/or INR, infrequently associated with hemorrhagic or thrombotic complications, were observed when bupropion was coadministered with warfarin.

Musculoskeletal: Muscle rigidity/fever/rhabdomyolysis, muscle weakness.

Nervous System: Aggression, coma, completed suicide, delirium, dream abnormalities, paranoid ideation, paresthesia, restlessness, suicide attempt, unmasking of tardive dyskinesia.

Skin and Appendages: Stevens-Johnson syndrome, angioedema, exfoliative dermatitis, urticaria.

Special Senses: Tinnitus, increased intraocular pressure.